Find Osemozotan Hydrochloride manufacturers, exporters & distributors on PharmaCompass

Osemozotan Hydrochloride

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 USDMF

1 API Suppliers
1 USDMF

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Osemozotan hydrochloride, Osemozotan hcl, 137275-80-0, Mkc-242, F0wkfypql8, 137275-80-0 (hcl)

Molecular Formula

C₁₉H₂₂ClNO₅

Molecular Weight

379.8 g/mol

InChI Key

GGNCUSDIUUCNKE-RSAXXLAASA-N

FDA UNII

F0WKFYPQL8

MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).

1 2D Structure

Osemozotan Hydrochloride

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

3-(1,3-benzodioxol-5-yloxy)-N-[[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine;hydrochloride

2.1.2 InChI

InChI=1S/C19H21NO5.ClH/c1-2-5-18-16(4-1)22-12-15(25-18)11-20-8-3-9-21-14-6-7-17-19(10-14)24-13-23-17;/h1-2,4-7,10,15,20H,3,8-9,11-13H2;1H/t15-;/m0./s1

2.1.3 InChI Key

GGNCUSDIUUCNKE-RSAXXLAASA-N

2.1.4 Canonical SMILES

C1C(OC2=CC=CC=C2O1)CNCCCOC3=CC4=C(C=C3)OCO4.Cl

2.1.5 Isomeric SMILES

C1[C@@H](OC2=CC=CC=C2O1)CNCCCOC3=CC4=C(C=C3)OCO4.Cl

2.2 Other Identifiers

2.2.1 UNII

F0WKFYPQL8

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 5-(3-((1,4-benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxole Hydrochloride

2. Mkc 242

3. Mkc-242

4. Osemozotan

2.3.2 Depositor-Supplied Synonyms

1. Osemozotan Hydrochloride

2. Osemozotan Hcl

3. 137275-80-0

4. Mkc-242

5. F0wkfypql8

6. 137275-80-0 (hcl)

7. Osemozotan (hydrochloride)

8. Mkc 242

9. 1,4-benzodioxin-2-methanamine, N-[3-(1,3-benzodioxol-5-yloxy)propyl]-2,3-dihydro-, Hydrochloride (1:1), (2s)-

10. Mci-242

11. 1,4-benzodioxin-2-methanamine, N-(3-(1,3-benzodioxol-5-yloxy)propyl)-2,3-dihydro-, Hydrochloride (1:1), (2s)-

12. 5-(3-((2s)-(1,4-benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol

13. Unii-f0wkfypql8

14. 1,4-benzodioxin-2-methanamine, 2,3-dihydro-n-(3-(1,3-benzodioxol-5-yloxy)propyl)-, Hydrochloride, (s)-

15. Schembl678900

16. Dtxsid00929762

17. Db05339

18. Hy-100426a

19. Cs-0018819

20. 3-(1,3-benzodioxol-5-yloxy)-n-[[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine;hydrochloride

21. 3-[(2h-1,3-benzodioxol-5-yl)oxy]-n-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]propan-1-amine--hydrogen Chloride (1/1)

22. 5-(3-((1,4-benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxole Hydrochloride, S-

2.4 Create Date

2005-08-09

3 Chemical and Physical Properties

Molecular Formula	C₁₉H₂₂ClNO₅
Molecular Weight	379.8 g/mol
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	7
Exact Mass	379.1186505 g/mol
Monoisotopic Mass	379.1186505 g/mol
Topological Polar Surface Area	58.2 Å²
Heavy Atom Count	26
Formal Charge	0
Complexity	409
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in anxiety disorders, depression, insomnia, and neurologic disorders.

5 Pharmacology and Biochemistry

5.1 Mechanism of Action

MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development by MediciNova both for the treatment of insomnia, as well as for anxiety disorders such as Generalized Anxiety Disorder (GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed no evidence of inducing genetic mutations, immune response or cancer. MN-305 has also proved to be consistently well-tolerated in clinical safety, efficacy and pharmacokinetic studies in over 1,200 subjects.

API SUPPLIERS